Research Analysts’ Recent Ratings Updates for Kindred Biosciences (KIN)

A number of research firms have changed their ratings and price targets for Kindred Biosciences (NASDAQ: KIN):

  • 5/22/2019 – Kindred Biosciences is now covered by analysts at Stifel Nicolaus. They set a “buy” rating on the stock.
  • 5/20/2019 – Kindred Biosciences was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 5/18/2019 – Kindred Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. “
  • 5/16/2019 – Kindred Biosciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $10.00 price target on the stock. According to Zacks, “Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. “
  • 5/7/2019 – Kindred Biosciences was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 4/26/2019 – Kindred Biosciences was given a new $25.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock. They wrote, “We believe KIN’s pipeline of novel animal health drugs will drive long-term shareholder value. As KIN advances its pipeline, we think investors should begin to appreciate the peak revenue potential of the products the company brings to market. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $25 price target. The Disclosure Section may be found on pages 3 – 5.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $25 price target.””
  • 4/18/2019 – Kindred Biosciences was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 4/11/2019 – Kindred Biosciences was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 4/10/2019 – Kindred Biosciences was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 4/10/2019 – Kindred Biosciences is now covered by analysts at Aegis. They set a “buy” rating and a $16.00 price target on the stock.
  • 4/5/2019 – Kindred Biosciences was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.

Shares of KIN stock opened at $8.28 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.10 and a quick ratio of 8.70. Kindred Biosciences Inc has a 12-month low of $8.04 and a 12-month high of $15.75. The stock has a market cap of $323.35 million, a price-to-earnings ratio of -5.18 and a beta of 0.37.

Kindred Biosciences (NASDAQ:KIN) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.01). The business had revenue of $0.52 million during the quarter, compared to analysts’ expectations of $1.95 million. Equities research analysts anticipate that Kindred Biosciences Inc will post -1.45 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Marshall Wace LLP purchased a new position in shares of Kindred Biosciences in the first quarter worth about $53,000. Legal & General Group Plc increased its holdings in shares of Kindred Biosciences by 24.6% in the third quarter. Legal & General Group Plc now owns 4,659 shares of the biopharmaceutical company’s stock worth $65,000 after buying an additional 920 shares during the period. BNP Paribas Arbitrage SA increased its holdings in shares of Kindred Biosciences by 83,433.3% in the first quarter. BNP Paribas Arbitrage SA now owns 7,518 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 7,509 shares during the period. Citigroup Inc. increased its holdings in shares of Kindred Biosciences by 28.6% in the first quarter. Citigroup Inc. now owns 9,810 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 2,181 shares during the period. Finally, Oxford Asset Management LLP purchased a new position in shares of Kindred Biosciences in the first quarter worth about $99,000. Hedge funds and other institutional investors own 57.82% of the company’s stock.

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Featured Article: What moving averages are used to define a golden cross?

Receive News & Ratings for Kindred Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.